FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing
The U.S. Food and Drug Administration this week began accepting applications for the FDA PreCheck...
The U.S. Food and Drug Administration this week began accepting applications for the FDA PreCheck...
Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...
Sanofi (NASDAQ: SNY) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...
China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...
The Center for Drug Evaluation (CDE) is seeking industry feedback on the 103rd batch of...
Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...
Chiesi Group announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended...
Novo Nordisk (NYSE: NVO) announced that Zhou Xiaping, Senior Vice President and President of Greater China,...
China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
Zhaoke Ophthalmology (HKG: 6622) announced that its UK partner Tenpoint Therapeutics has received FDA clearance...
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the National Medical Products Administration (NMPA) has approved...
AstraZeneca (AZ, NASDAQ: AZN) announced a plan to invest RMB 100 billion (USD 14.4 billion) :in China by 2030 to...
Ascletis Pharma Inc (HKG: 1672) announced positive top‑line results from the open‑label Phase III study (NCT06248008)...
Thermo Fisher Scientific Inc. (NYSE: TMO) reported fourth‑quarter revenue of $12.21 billion , up 7% year‑on‑year (YOY),...
TYK Medicines, Inc. (HKG: 2410) announced that its Category 1 drug asandeutertinib (TY‑9591), a third‑generation EGFR...
Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK) reported third‑quarter fiscal 2025 revenue of 3,411.2 billion yen (USD 22.17 billion), down...
Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong...
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that a supplementary Biologics License Application (sBLA)...